NIOX Group PLC (NIOX) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.130x

Based on the latest financial reports, NIOX Group PLC (NIOX) has a cash flow conversion efficiency ratio of 0.130x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX8.80 Million ≈ $1.07K USD) by net assets (GBX67.60 Million ≈ $8.22K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NIOX Group PLC (NIOX) net asset quality to measure how much of total assets are equity-financed.

NIOX Group PLC - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how NIOX Group PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check NIOX cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

NIOX Group PLC Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of NIOX Group PLC ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
G-Tec Jainx Education Limited
NSE:GTECJAINX
N/A
EQTEC plc
LSE:EQT
-0.273x
ACRUX Ltd
AU:ACR
-3.930x
Playfair Mining Ltd.
V:PLY
0.001x
Capstone Holding Corp. Common Stock
NASDAQ:CAPS
-0.249x
Oriental Culture Holding Ltd
NASDAQ:OCG
0.009x
PROSPECT RIDGE RESOURCES
F:0ED
-0.292x
Inomin Mines Inc
V:MINE
-0.133x

Annual Cash Flow Conversion Efficiency for NIOX Group PLC (2013–2025)

The table below shows the annual cash flow conversion efficiency of NIOX Group PLC from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see market value of NIOX Group PLC.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 GBX67.60 Million
≈ $8.22K
GBX15.80 Million
≈ $1.92K
0.234x -19.15%
2024-12-31 GBX59.50 Million
≈ $7.24K
GBX17.20 Million
≈ $2.09K
0.289x +108.83%
2023-12-31 GBX83.80 Million
≈ $10.20K
GBX11.60 Million
≈ $1.41K
0.138x 0.00%
2023-12-30 GBX83.80 Million
≈ $10.20K
GBX11.60 Million
≈ $1.41K
0.138x +69.21%
2022-12-31 GBX81.90 Million
≈ $9.96K
GBX6.70 Million
≈ $815.20
0.082x 0.00%
2022-12-30 GBX81.90 Million
≈ $9.96K
GBX6.70 Million
≈ $815.20
0.082x +290.34%
2021-12-31 GBX66.80 Million
≈ $8.13K
GBX1.40 Million
≈ $170.34
0.021x 0.00%
2021-12-30 GBX66.80 Million
≈ $8.13K
GBX1.40 Million
≈ $170.34
0.021x +105.80%
2020-12-31 GBX66.10 Million
≈ $8.04K
GBX-23.90 Million
≈ $-2.91K
-0.362x 0.00%
2020-12-30 GBX66.10 Million
≈ $8.04K
GBX-23.90 Million
≈ $-2.91K
-0.362x -22.16%
2019-12-31 GBX84.80 Million
≈ $10.32K
GBX-25.10 Million
≈ $-3.05K
-0.296x 0.00%
2019-12-30 GBX84.80 Million
≈ $10.32K
GBX-25.10 Million
≈ $-3.05K
-0.296x -33.41%
2018-12-31 GBX183.00 Million
≈ $22.27K
GBX-40.60 Million
≈ $-4.94K
-0.222x 0.00%
2018-12-30 GBX183.00 Million
≈ $22.27K
GBX-40.60 Million
≈ $-4.94K
-0.222x -43.13%
2017-12-31 GBX371.60 Million
≈ $45.21K
GBX-57.60 Million
≈ $-7.01K
-0.155x 0.00%
2017-12-30 GBX371.60 Million
≈ $45.21K
GBX-57.60 Million
≈ $-7.01K
-0.155x +14.54%
2016-12-31 GBX312.60 Million
≈ $38.03K
GBX-56.70 Million
≈ $-6.90K
-0.181x 0.00%
2016-12-30 GBX312.60 Million
≈ $38.03K
GBX-56.70 Million
≈ $-6.90K
-0.181x -43.32%
2015-12-31 GBX440.90 Million
≈ $53.64K
GBX-55.80 Million
≈ $-6.79K
-0.127x 0.00%
2015-12-30 GBX440.90 Million
≈ $53.64K
GBX-55.80 Million
≈ $-6.79K
-0.127x +34.56%
2014-12-31 GBX190.80 Million
≈ $23.21K
GBX-36.90 Million
≈ $-4.49K
-0.193x 0.00%
2014-12-30 GBX190.80 Million
≈ $23.21K
GBX-36.90 Million
≈ $-4.49K
-0.193x +67.50%
2013-12-31 GBX30.05 Million
≈ $3.66K
GBX-17.88 Million
≈ $-2.18K
-0.595x 0.00%
2013-12-30 GBX30.05 Million
≈ $3.66K
GBX-17.88 Million
≈ $-2.18K
-0.595x --

About NIOX Group PLC

LSE:NIOX UK Medical Devices
Market Cap
$3.20 Million
GBX26.26 Billion GBX
Market Cap Rank
#29351 Global
#577 in UK
Share Price
GBX62.40
Change (1 day)
+1.96%
52-Week Range
GBX54.40 - GBX76.00
All Time High
GBX306.79
About

NIOX Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis, monitoring, and management of asthma and COPD worldwide. The company offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device, sensors, individual disposable mouthpieces, and breathing handles for the measurement of fractional exhaled nitric oxide … Read more